Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Relmada Therapeutics, Inc. RLMD
$3.01
-$0.15 (-5.05%)
На 18:02, 12 мая 2023
+149.17%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
100079840.00000000
-
week52high
38.68
-
week52low
1.81
-
Revenue
0
-
P/E TTM
-1
-
Beta
0.15951500
-
EPS
-5.30000000
-
Last Dividend
0.00000000
-
Next Earnings Date
03 мая 2023 г. в 20:00
Описание компании
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Oppenheimer | Outperform | Outperform | 09 мая 2022 г. |
| Goldman Sachs | Buy | Buy | 24 мар 2022 г. |
| SVB Leerink | Outperform | Outperform | 20 дек 2021 г. |
| Mizuho | Buy | 18 ноя 2021 г. | |
| SunTrust Robinson Humphrey | Buy | 25 ноя 2020 г. | |
| Guggenheim | Buy | Buy | 06 сент 2022 г. |
| Goldman Sachs | Buy | Buy | 23 сент 2022 г. |
| Guggenheim | Neutral | Buy | 14 окт 2022 г. |
| Goldman Sachs | Neutral | Buy | 14 окт 2022 г. |
| Oppenheimer | Perform | Outperform | 13 окт 2022 г. |
| SVB Leerink | Outperform | Outperform | 23 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| O'Gorman Cedric | D | 400000 | 400000 | 06 янв 2023 г. |
| Ence Chuck | D | 0 | 200000 | 16 дек 2022 г. |
| Shenouda Maged | D | 0 | 200000 | 16 дек 2022 г. |
| TRAVERSA SERGIO | D | 0 | 300000 | 16 дек 2022 г. |
| SCHMIDT ERIC THOMAS | A | 57042 | 57042 | 16 дек 2022 г. |
| Shenouda Maged | A | 194917 | 194917 | 16 дек 2022 г. |
| TRAVERSA SERGIO | A | 323517 | 323517 | 16 дек 2022 г. |
| CASAMENTO CHARLES J | A | 57042 | 57042 | 16 дек 2022 г. |
| Ence Chuck | A | 197123 | 197123 | 16 дек 2022 г. |
| GLASSPOOL JOHN | A | 57042 | 57042 | 16 дек 2022 г. |
Новостная лента
Relmada Therapeutics shares decline 40% on Thursday
Market Watch
08 дек 2022 г. в 08:39
Shares of Relmada Therapeutics Inc. RLMD, -0.95% tumbled about 40% in premarket trading on Thursday, the day after the company said its experimental depression drug did not meet the primary endpoint in a Phase 3 clinical trial. The stock closed Wednesday at $4.16, a three-year low.
Relmada Therapeutics, Inc. (RLMD) Q3 2022 Earnings Call Transcript
Seeking Alpha
12 ноя 2022 г. в 08:33
Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Brian Ritchie - LifeSci Advisors Sergio Traversa - Chief Executive Officer Maged Shenouda - Chief Financial Officer Maurizio Fava - Chairman, Harvard Psychiatry Department Conference Call Participants Guofang Li - SVB Securities Uy Ear - Mizuho Yatin Suneja - Guggenheim Partners Andrea Tan - Goldman Sachs Andrew Tsai - Jefferies Jay Olson - Oppenheimer Joon Lee - Truist Securities Operator Good afternoon. My name is Kathy, and I'll be your conference operator for today.
Steven Cohen's Firm Boosts Stakes in Relmada and Immunic
GuruFocus
25 окт 2022 г. в 17:52
Steven Cohen (Trades, Portfolio), chairman and CEO of Point72 Asset Management, disclosed in regulatory filings that his firm established a position in Progress Acquistion Corp. ( PGRWU , Financial) and boosted its holdings of Relmada Therapeutics Inc. ( RLMD , Financial) and Immunic Inc. ( IMUX , Financial).
Relmada (RLMD) Lead Candidate Fails Late-Stage Depression Study
Zacks Investment Research
14 окт 2022 г. в 14:18
Relmada's (RLMD) phase III study, evaluating REL-1017 in major depressive disorder, fails to achieve statistical significance. Shares plunge 80% following the news.
Why Is Relmada (RLMD) Stock Down 78% Today?
InvestorPlace
13 окт 2022 г. в 10:06
Source: Shutterstock Relmada Therapeutics (NASDAQ: RLMD ) stock is plummeting on Thursday as investors react to results from a Phase 3 clinical trial. Unfortunately for RLMD stock, its RELIANCE III study didn't go as planned.